trbherb

Lupeol Powder 98%

stars, based on 0reviews
10000items available

Product Name:Lupeol Powder 98%

Botanic Source:Mango, Acacia visco, Abronia villosa, Dandelion coffee.

CAS No:545-47-1

Colour: White to off-white powder with characteristic odor and taste

Specification:≥98% HPLC

GMO Status:GMO Free

Packing: in 25kgs fiber drums

Storage:Keep container unopened in cool, dry place,Keep away from strong light

Shelf Life:24 months from date of production

 

Lupeol powder is a new dietary triterpene. Lupeol is a brand-new androgen receptor blocker.

Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpene with antioxidant, antitumor and anti-inflammatory activities. Lupeol is a potent androgen receptor inhibitor and can be used in cancer research, especially in prostate cancer with androgen-dependent phenotype (ADPC) and castration-resistant phenotype (CRPC).

 

Biological Activity:

Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC)[1].

 

In Vitro Research:

Lupeol is a potent AR inhibitor that can be developed as a potential drug for the treatment of human prostate cancer (CaP). Lupeol (10–50 μM) treatment for 48 h resulted in a dose-dependent growth inhibition of androgen-dependent phenotype (ADPC) cells, namely LAPC4 and LNCaP cells, with IC50 of 15.9 and 17.3 μM, respectively. Lupeol also inhibited the growth of 22Rν_1 with an IC50 of 19.1 μM. In addition, Lupeol inhibited the growth of C4-2b cells with an IC50 of 25 μM. Lupeol has the potential to inhibit the growth of CaP cells of both ADPC and CRPC phenotypes. Androgens are known to drive the growth of CaP cells through activation of the AR[1]

 

In Vivo Research:

Lupeol is an effective drug with the potential to inhibit the tumorigenicity of CaP cells in vivo. Total circulating serum PSA levels (secreted by implanted tumor cells) were measured at the end of the study on day 56. On day 56 post-implantation, PSA levels ranging from 11.95-12.79 ng/mL were observed in control animals with LNCaP tumors and C4-2b tumors, respectively. However, Lupeol-treated counterparts exhibited reduced serum PSA levels ranging from 4.25-7.09 ng/mL. Tumor tissues from animals treated with Lupeol exhibited reduced serum PSA levels compared to controls[1]

 

 

Recent Reviews
+